The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

Nature：非小细胞肺癌新靶点CLIP1-LTK被发现，劳拉替尼效果不错@MedSci

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research

LTK and ALK promote neuronal polarity and cortical migration by

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Frontiers Recent progress in targeted therapy for non-small cell lung cancer

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer - ScienceDirect

Targeting Oncogenic Driver Mutations in Lung Cancer

Recombinant Anti-LTK antibody [EPR5175(2)] (ab129155)